1. France Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
AB Science SA

AB Science SA

0.57
EUR
+0.02
(+4.42%)
57.01MMarket Cap
Apr 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.06
0.06
0.07
0.04
0.05
0.05
0.04
0.04
0.03
0.02
0.02
0.02
0.02
- -
Basic EPS, GAAP
-0.45
-0.49
-0.78
-0.78
-0.75
-0.69
-0.55
-0.34
-0.3
-0.29
-0.24
-0.15
-0.03
- -
Free Cash Flow per Basic Share
-0.4
-0.45
-0.7
-0.95
-0.64
-0.71
-0.38
-0.31
-0.37
-0.38
-0.35
0.01
-0.07
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
-0.48
-0.49
-0.12
0.26
-0.36
-0.62
-0.43
-0.5
-0.76
-0.41
-0.37
-0.26
-0.37
Tangible Book Value per Share
-0.03
-0.52
-0.54
-0.17
0.22
-0.4
-0.65
-0.46
-0.53
-0.8
-0.44
-0.39
-0.28
-0.39
Basic Weighted Avg Shares
33
33
34
36
36
38
39
44
48
47
50
53
61
54
Sales/Revenue/Turnover
2
2
2
2
2
2
2
2
2
1
1
1
1
- -
Operating Margin (%)
-712.42
-724.3
-1,136.78
-2,003.05
-1,633.35
-1,701.53
-1,112.29
-931.71
-859.24
-1,663.67
-1,384.43
-567.44
54.43
- -
Depreciation Expense
1
- -
- -
1
- -
1
1
1
2
- -
2
1
- -
- -
Net Income, GAAP
-15
-16
-27
-28
-27
-26
-22
-15
-14
-14
-12
-8
-2
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-755.87
-767.6
-1,169.7
-1,836.6
-1,559.63
-1,532.1
-1,384.28
-950.41
-900
-1,421.19
-1,235.57
-730.5
-132.62
- -
Working Capital
29
16
13
16
30
2
-5
4
1
-2
1
-6
-1
-6
LT Debt
22
23
22
- -
- -
- -
2
2
8
19
17
15
19
15
Total Equity
- -
-16
-17
-5
11
-15
-27
-20
-23
-36
-21
-24
-17
-24
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-557.67
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
2
2
4
LT Borrowings
17
16
14
LT Finance Leases
- -
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
52
65
Market Capitalization
182
58
57

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
19
14
15
Cash, Cash Equivalents & STI
6
9
8
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
19
18
20
Payables & Accruals
- -
- -
- -
ST Debt
2
2
4
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-57.13%
3.36%
-27.6%
Free Cash Flow
-143.7%
-282.52%
-1,335.41%
Net Income, GAAP
-18.62%
-27.3%
-80.12%
Sales/Revenue/Turnover
-4.53%
-3.52%
9.51%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1
2024
- -
- -
1
2025
- -
- -
1

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.24
2024
- -
- -
-0.15
2025
- -
- -
-0.03

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Stéphane Ledermann
Full Time Employees
36
Sector
Health technology
Industry
Pharmaceuticals: other
Address
3, Avenue George V Paris IF France 75008
IPO Date
Apr 27, 2010
Website
ab-science.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
AB Science S.A. (Euronext: AB) is a clinical-stage French pharmaceutical company that researches, develops and commercializes protein kinase inhibitors and related targeted therapies for cancers, inflammatory diseases, neurodegenerative disorders and other conditions with high unmet medical needs in humans and veterinary medicine; its lead product masitinib, a highly selective tyrosine kinase inhibitor already approved for veterinary use, advances in late-stage human trials for amyotrophic lateral sclerosis (ALS), multiple sclerosis, oncology and other indications including a new confirmatory Phase 3 study (AB23005) authorized by the FDA and select European countries in 2025, while its second key compound AB8939, a next-generation microtubule destabilizer, progresses through Phase 1/2 in acute myeloid leukemia (AML) with promising early efficacy data and plans for an expansion cohort. Founded in 2001 and headquartered at 3 Avenue George V in Paris, France, the company employs around 40 staff primarily focused on R&D, operates globally through clinical programs in Europe, North America and beyond including a U.S. subsidiary in New Jersey, and markets masitinib for veterinary applications while pursuing human approvals. Recent developments include multiple 2025 capital raises totaling over EUR 9 million through private placements and its PACT program with Alpha Blue Ocean to fund AB8939 advancement and masitinib studies, ongoing re-examination of masitinib marketing authorizations for ALS with the EMA and Health Canada, and operational restructuring to prioritize its dual-platform pipeline amid reduced bank debt.